ReviewJournal of the American Academy of Dermatology2014
Skin cancer in organ transplant recipients: more than the immune system.
Review in Journal of the American Academy of Dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis.Clinical rheumatology · 2020Pooled it
- Knowledge and Risk Perception Regarding Skin Cancer in Immunosuppressed Patients: A Systematic Review and Meta-Analysis.European journal of investigation in health, psychology and education · 2026Review
- Human papillomavirus-associated skin cancers among organ transplant recipients: A systematic review and meta-analysis.Caspian journal of internal medicine · 2025Review
- Article
- Frequency of skin diseases in renal transplant recipients and patients with chronic kidney disease in a tertiary center: a cross-sectional study.Sao Paulo medical journal = Revista paulista de medicina · 2024Observational
- An Insight on Skin Cancer About Different Targets With Update on Clinical Trials and Investigational Drugs.Current drug delivery · 2024Review
- Immunomodulators for Non-Melanoma Skin Cancers: Updated Perspectives.Clinical, cosmetic and investigational dermatology · 2023Review
- Mohs micrographic surgery for keratinocyte carcinomas: clinicopathological predictors of the number of stages.Proceedings (Baylor University. Medical Center) · 2023Article
- NONMELANOMA SKIN CANCER IN A HEART TRANSPLANT PATIENT: A CASE REPORT AND REVIEW OF THE LITERATURE.Acta clinica Croatica · 2022Review
- RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates.Journal of clinical medicine · 2021Review
- Recurrent squamous cell carcinoma in a post cardiac transplant patient.International journal of surgery case reports · 2021Article
- Genomic profiling of late-onset basal cell carcinomas from two brothers with nevoid basal cell carcinoma syndrome.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Article
- Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma.Genome medicine · 2020Article
- Risk Factors and Outcomes of Nonmelanoma Skin Cancer in Children and Young Adults.The Journal of pediatrics · 2019Article
- Aggressive Squamous Cell Carcinoma in Organ Transplant Recipients.JAMA dermatology · 2019Article
- Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma.JCI insight · 2018Article
- The Use of Noninvasive Optical Coherence Tomography to Monitor the Treatment Progress of Vismodegib and Imiquimod 5% Cream in a Transplant Patient with Advanced Basal Cell Carcinoma of the Nose.The Journal of clinical and aesthetic dermatology · 2016Article
- Ultraviolet Radiation Exposure and Its Impact on Skin Cancer Risk.Seminars in oncology nursing · 2016Review
- Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden.BMJ (Clinical research ed.) · 2016Article
- Different Course of Nonpigmented Skin Cancers in Patients Treated with Immunosuppression after Organ Transplantation: A Case Series.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Organ transplant recipients (OTRs) are at increased risk of developing nonmelanoma skin cancers. This has long been thought to be caused by immunosuppression and viral infection. However, skin cancer risk among individuals with AIDS or iatrogenic immunodeficiency does not approach the levels seen in OTRs, suggesting other factors play a critical role in oncogenesis. In clinical trials of OTRs, switching from calcineurin inhibitors to mammalian target of rapamycin inhibitors consistently led to a significant reduction in the risk of developing new skin cancers. New evidence suggests calcineurin inhibitors interfere with p53 signaling and nucleotide excision repair. These two pathways are associated with nonmelanoma skin cancer, and squamous cell carcinoma in particular. This finding may help explain the predominance of squamous cell carcinoma over basal cell carcinoma in this population. Mammalian target of rapamycin inhibitors do not appear to impact these pathways. Immunosuppression, viral infection, and impaired DNA repair and p53 signaling all interact in OTRs to create a phenotype of extreme risk for nonmelanoma skin cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.